BACKGROUND: Cough is common in patients with lung cancer, and current antitussive treatments are suboptimal. There are little published data describing cough in patients with lung cancer or work assessing clinical associations. The aim of this study is to fill that gap.
Cough in patients with lung cancer is an unmet clinical need for which morbidity and distress have been underestimated. 1, 2 It impacts on physical, psychologic, and social aspects of daily living 2, 3 ; contributes to pain, fatigue, insomnia, and dyspnea 2 ; increases anxiety in patients and carers 2, 4 ; and leads to social isolation. 2 Although cough is a common symptom, its prevalence varies widely between studies from 31.5% to 93%. 5, 6 This may be explained by differing methodologies and approaches to cough assessment and heterogeneous populations of patients with lung cancer evaluated. Notably, there is very little understanding of the possible mechanisms underlying cough among patients with lung cancer, 7 which has implications for the development of effective antitussive therapies. Furthermore, studies of cough in patients with lung cancer should ideally use validated objective and subjective cough assessment tools.
Our group has recently demonstrated the validity of subjective and objective cough assessment tools for patients with lung cancer, including the cough severity visual analog scale (VAS), the Manchester Cough in Lung Cancer (MCLC) Scale to assess cough impact, and the 24-hour ambulatory cough monitoring (ACM) to assess cough frequency. 5, 8 This provides opportunity to assess and describe cough in the lung cancer population and in the future to use in trials of novel antitussive agents in patients with lung cancer. To design such studies, information about cough prevalence, severity, impact, clinical associations, causes, and treatment is required. There is a paucity of data on these factors in patients with lung cancer probably because of inadequate cough assessment tools and limited research where cough is the primary outcome.
Given the availability of lung cancer-specific tools for cough assessment and emerging data on cough mechanisms and novel antitussive therapies, this study was conducted to describe the characteristics of cough in patients with lung cancer and to obtain information on its change over time. Specific objectives included the following: (1) to determine how cough severity, frequency, and impact in patients with lung cancer changes over time; and (2) to assess for clinical factors associated with cough severity and cough impact over time.
Methods
This was a longitudinal observational study. Patients attending a thoracic oncology outpatient clinic were invited to enroll in a 60-day single-arm cohort study to assess cough. Patients were eligible to participate if they had a diagnosis of lung cancer, reported a cough on direct questioning by the treating team or researchers, were able to comply with the study schedule, and were able to read and respond to questions in English. Written informed consent was obtained from all study participants. The study was approved by the local research ethics committee (REC 11/NW/0374).
Nonconsecutive patients on prespecified days were screened, and those reporting cough and agreeing to participate completed a set of assessments at study entry (day 0), day 30, and day 60 (Fig 1, groups  A and B) . Patients completed a number of self-reported scales. A subsample also underwent a 24-h ACM on study entry and at day 60 (group B). Eligible participants were assigned to group A if they consented to the study but declined 24-h ACM, or to group B if they consented both to the study and to 24-h ACM.
Assessment Tools
MCLC Scale: The MCLC Scale is a 10-item lung cancer cough-specific quality of life questionnaire which includes items on cough frequency, distress, impact, and severity. 9 Scores range from 1 to 50, with higher scores indicating a worse cough-related quality of life. This was completed at study entry, day 30, and day 60.
Cough Severity VAS: The cough severity VAS 10 is a 100-mm line marked with no cough at 0 mm and worst cough at 100 mm. Patients were asked to mark along the line to represent their perceived cough severity. This was completed at study entry, day 30, and day 60.
Cough Severity Diary: The cough severity diary (CSD) 11 is a cough assessment tool that has seven 11-point scales ranging from scores of 0 to 10 that assess severity in terms of disruptiveness (two items), frequency (three items), and intensity (two items). The CSD total score, representing the magnitude of cough severity, is calculated by averaging across all seven items. Higher scores indicate worse cough severity. This was completed at study entry and day 60.
The single item (item 31) for the assessment of cough from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire's lung cancer module 12 was also used. It states the following: During the past week, how much did you cough? It was answered on a 4-point Likert scale ranging from not at all to very much. This was completed at study entry and day 60.
Common Terminology Criteria for Adverse Events Version 4.0: The Common Terminology Criteria for Adverse Events version 4.0 is a symptom tool which documents clinician-assessed cancer treatmentrelated toxicities. 13 The cough item is a 3-point scale, where high scores represent highest symptomatology. This was completed at days 0 and 60.
Brief Reflux Inventory: The Brief Reflux Inventory (BRI) is a 5-item scale to assess reflux.
14 Its items relate to symptoms of regurgitation, chest pain/burning, and nocturnal symptoms. Each item has five response categories: never, rarely, once a month to once a week, at least twice a week, and daily. The scale is scored from 0 (never) to 5 (daily). The total weighted score is the sum of the weighted scores for the five individual items of the inventory. Patients with a total BRI score > 31.6 are defined as those with reflux disease. This was completed at days 0 and 60.
World Health Organization Performance Status: The World Health Organization Performance Status categorizes a patient's overall health status. 15 Scores range from 0 to 5, with higher scores indicating a poorer overall performance status. The World Health Organization Performance Status was completed by a researcher on days 0 and 60.
Cough frequency was assessed using an objective ACM at days 0 and 60 only. ACM is an objective cough assessment tool to determine the frequency of cough events. 16, 17 A contact sensor is applied below the sternal notch and a microphone is attached to the lapel connected to the VitaloJAK Cough Monitor (Vitalograph Ltd), which is carried in a waist bag. Validated custom-written software algorithms are used to compress the recording from 24 h to a shorter file by detecting all potential cough sounds. Trained staff then listen to the reduced file and manually tag the number of explosive cough sounds within the recording using an audio editing software package (Adobe Audition 3.0; Adobe) to produce an hour by hour cough count report, previously validated.
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Sample Size Estimation
We estimated that 178 patients would be recruited for a sample size for analysis of 160. This is based on Peduzzi et al 21 for 10 participants per variable in binary logistic regression, assuming an attrition rate of 10%, the estimated percentage presenting with a severe cough to be 50%, and the number of cough predictors to be eight. The clinical factors investigated were time from diagnosis, age, sex, smoking (never vs current/ex), stage (early vs late), histology chestjournal.org (small cell lung cancer vs non-small cell lung cancer), tumor location (peripheral vs central), presence of comorbidities, and comedications. Of note, when squamous cell and adenocarcinoma were analyzed separately, histologic subtypes still did not predict cough severity or impact.
Forty patients were required for ACM to detect medium-to-high (0.40) and high (0.50) correlations between quality of life and subjective measures and ACM. The numbers needed at 5% significance and 80% power with a one-sided test were 37 and 23, respectively, for Pearson and Spearman correlations.
Statistical Analysis
Statistical analyses were performed using SPSS v.19.0 (SPSS Inc). Descriptive statistics were used to summarize the data. Multivariate linear regression analyses, adjusted for baseline scores, were used to determine factors associated with cough severity, frequency, and impact and their change over time.
Results
Sample Characteristics
There were 696 patients screened, and 257 reported cough. From these, 178 patients consented to participate in the study, 177 completed study entry data, and 153 patients completed assessments at day 60 (attrition rate, 14%) (Fig 1) . The clinical characteristics of the study population are shown in Table 1 .
Cough Characteristics at Study Entry
The The third is the proportion of patients who were in precancer therapy.
In the overall study, population cough scores improved over the course of the study, irrespective of the subjective cough assessment tool used (Fig 2) . Most of the improvement occurred during the day 0 to 30 interval, rather than the day 0 to 60 interval for the VAS, MCLC Scale, and Common Terminology Criteria for Adverse Events. The CSD and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire's lung cancer module item 31 (how often did you cough?) were not assessed on day 30; however, overall scores also improved between day 0 and day 60. There was significant overlap between the cough scores at all assessment points. In contrast, the objective 24-h ACM rates did not significantly change between days 0 and 60.
Clinical Factors Associated With Cough Impact (MCLC Scale) and Cough Severity (VAS) Scores
The analyses were conducted for patients at study entry and for change in cough over time periods day 0 to day 30 and day 0 to day 60. Clinical factors associated with both cough severity (VAS score) and cough impact on quality of life (MCLC Scale score) were determined on univariate and multivariate analyses. These are shown in Tables 3-5 . Similar clinical characteristics were associated with cough severity and cough impact at study entry and over time. At study entry, performance status was significantly associated with both cough severity VAS and cough impact MCLC Scale scores on both univariate and multivariate analyses. Notably, cancer characteristics (ie, cancer stage, histology) were not associated with cough severity/impact scores; neither was smoking or COPD. However, gastrointestinal symptoms, specifically nausea and reflux, were associated with cough severity and cough impact at study entry in the univariate analysis.
Cough severity/impact and reported use of opioids and other antitussive treatments exhibited interesting associations. At study entry, cough severity was worse in those taking antitussive therapies and impact was worse in those on opioids on univariate analysis. However, those taking opioids and antitussives at 30-and 60-day follow-up where more likely to have some improvements in cough severity and/or impact. Similarly, those on antitussive therapies were more likely to report improvement in cough severity over time.
Discussion
To our knowledge, this study is the first study to describe the characteristics of cough in patients with lung cancer longitudinally over a 60-day period using validated subjective cough assessment tools and objective ACM. The use of these assessments provides a benchmark of cough severity, frequency, impact, change over time, and clinical associations in a real-world population of patients with lung cancer.
We previously showed that 57% of consecutive patients with lung cancer (n ¼ 223) experienced cough, with most stating that their cough warranted treatment and with 23% reporting a painful cough. 22 In this study, over two-thirds of patients with lung cancer and a cough expressed that their cough was severe enough to warrant treatment. The median cough severity scores at study entry demonstrated that this cohort of patients with lung cancer has a severe and frequent cough, worse than reported in patients with COPD and asthma, 18, 19 and as severe and frequent as in patients who present to specialist chronic cough clinics with cough as their primary symptom. 20 Despite this, only 15% of patients in this study reported the use of over-the-counter antitussives. One possible explanation may be that patients themselves, or healthcare professionals, recognize the lack of efficacy of such treatments. It is notable that at study entry, antitussive, opioid, and steroid therapies were associated with a worse cough. We did not ascertain whether opioid treatment was prescribed specifically to treat cough as opposed to pain or breathlessness. However, we observed that within individuals opioid use was associated with improvement in cough severity and impact over time, implying a potential 
Baseline VAS score
Higher baseline score ¼ greater improvement
Baseline MCLC Scale score
See Table 2 the associations between cough and reflux/regurgitation at study entry are reminiscent of the reflux-cough relationships well described in patients with refractory chronic cough, it was also revealing that nausea, another vagally mediated symptom, was significantly associated with cough. Although coughing may lead to nausea and vomiting, a cluster analysis of symptoms from a broad range of patients with cancer suggested gastrointestinal symptoms including nausea tend to be coreported by patients with cough and breathlessness. 24 Such clusters of coreported symptoms may be explained by shared physiologic mechanisms, and this particular cluster of symptoms is in keeping with a set of symptoms mediated by the vagus nerve.
Although this study was longitudinal, the time period of 60 days is short compared with the overall disease trajectory. This may have been partly overcome by the fact that patients were enrolled at any stage on their disease trajectory in a relatively large cohort of patients. However, few patients enrolled in the study were receiving curative-intent treatment and few patients were at the end of life; therefore, the severity and burden of cough in those groups is not well represented. The day 30 
Higher baseline score ¼ greater improvement P ¼ .018 P < .001 NS .
Baseline MCLC Scale score
Higher baseline score ¼ greater improvement NS . P < .001 P < .001
See Table 2 and 3 legends for expansion of abbreviations. a Item 5 of the Brief Reflux Inventory was excluded because it contained cough within the following question: Are you ever woken up at night by a feeling of heartburn, coughing, or choking?
chestjournal.org assessment was limited to the MCLC Scale and VAS only to reduce the burden of a day 30 hospital visit. Because the VAS required completion at home and return by post, only 62% patients completed this scale at day 30, limiting the analysis of this outcome measure. Also, pulmonary function tests were obtained by the use of a handheld spirometry device, which can underestimate changes in pulmonary function.
In conclusion, using validated objective and subjective cough assessment tools, we confirm that cough is a severe and distressing symptom in patients with lung cancer. Current antitussive therapies have limited efficacy with a weak evidence base. 25 Importantly, gastrointestinal symptoms demonstrated an association with cough rather than smoking, cancer stage, location, treatment, and COPD. Research in the noncancer setting has elucidated central nervous system circuitry and pathways common to cough and the gastrointestinal tract leading to a more comprehensive understanding of cough neurochemistry and higher order control of coughing. 26, 27 As a result, new potential targets for antitussive therapies have been identified that may be relevant to patients with lung cancer. 28, 29 Specific management of reflux and nausea may also alleviate cough in this population of patients.
